Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study.
Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study.
复制标题
DOI：
10.1186/1475-2840-12-5
复制
发表时间：
2013-01-07
影响因子：
9.3
通讯作者：
JAPAN-ACS Investigators
中科院分区：
文献类型：
--
作者：
Fukushima Y;Daida H;Morimoto T;Kasai T;Miyauchi K;Yamagishi S;Takeuchi M;Hiro T;Kimura T;Nakagawa Y;Yamagishi M;Ozaki Y;Matsuzaki M;JAPAN-ACS Investigators
日本评估匹伐他汀和阿托伐他汀治疗急性冠脉综合征(JAPAN-ACS)试验表明，对急性冠脉综合征患者进行早期积极的他汀类药物治疗可显著减少斑块体积(PV)。晚期糖基化终产物(AGEs)及其受体(RAGE)可能导致糖尿病(DM)的血管病变，并可能影响冠脉PV的发展。日本-急性冠脉综合征的本子研究调查了年龄与RAGE和PV之间的关系。对急性冠脉综合征患者行血管内超声(IVUS)引导下经皮冠状动脉介入治疗(PCI)，然后开始他汀类药物治疗(4 mg/d或20 mg/d阿托伐他汀)。在208名日本急性冠脉综合征受试者中，在介入治疗后8-12个月，分别在非致病节段>；5 mm处进行静脉超声检查，并测定血清AGEs水平和可溶性RAGE(SRAGE)。在基线时，糖尿病患者和非糖尿病患者之间的AGEs或sRAGE水平没有发现差异。经他汀类药物治疗后，AGEs水平从8.6U/ml降至8.0U/ml(p<；0.001)，而sRAGE水平无明显变化。PV的变化与AGE和SRAGE水平的变化之间没有显著的相关性。然而，即使在多变量Logistic回归模型中调整了DM因素后，基线AGEs水平与斑块进展显著相关(优势比1.21；95%可信区间1.01-1.48；p=0.044)。在日本-ACS试验中，高基线AGEs水平与斑块进展相关。这种关系是独立于DM的。这些发现表明AGEs可能与长期的血糖控制和ACS的其他氧化应激有关。NCT00242944
The Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial demonstrated that early aggressive statin therapy in patients with ACS significantly reduces plaque volume (PV). Advanced glycation end products (AGEs) and the receptors of AGEs (RAGE) may lead to angiopathy in diabetes mellitus (DM) and may affect on the development of coronary PV. The present sub-study of JAPAN-ACS investigates the association between AGEs and RAGE, and PV. Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment (either 4 mg/day of pitavastatin or 20 mg/day of atorvastatin), in patients with ACS. In the 208 JAPAN-ACS subjects, PV using IVUS in non-culprit segment > 5 mm proximal or distal to the culprit lesion and, serum levels of AGEs and soluble RAGE (sRAGE) were measured at baseline and 8–12 months after PCI. At baseline, no differences in the levels of either AGEs or sRAGE were found between patients with DM and those without DM. The levels of AGEs decreased significantly with statin therapy from 8.6 ± 2.2 to 8.0 ± 2.1 U/ml (p < 0.001), whereas the levels of sRAGE did not change. There were no significant correlations between changes in PV and the changes in levels of AGEs as well as sRAGE. However, high baseline AGEs levels were significantly associated with plaque progression (odds ratio, 1.21; 95% confidence interval, 1.01 - 1.48; p = 0.044) even after adjusting for DM in multivariate logistic regression models. High baseline AGEs levels were associated with plaque progression in the JAPAN-ACS trial. This relationship was independent of DM. These findings suggest AGEs may be related to long-term glucose control and other oxidative stresses in ACS. NCT00242944
登录
查看更多内容
DOI：
10.1111/j.1440-1746.2007.04943.x
发表时间：
2007-07-01
影响因子：
4.1
作者：
Hyogo, Hideyuki;Yamagishi, Sho-ichi;Tazuma, Susumu
通讯作者：
Tazuma, Susumu
影响因子：
9.3
作者：
Maeda, Sayaka;Matsui, Takanori;Yamagishi, Sho-ichi
通讯作者：
Yamagishi, Sho-ichi
影响因子：
9.3
作者：
An, Xuanqi;Yu, Dong;Xiong, Xiaowei
通讯作者：
Xiong, Xiaowei
DOI：
10.1016/s0735-1097(01)01175-5
发表时间：
2001-04-01
影响因子：
24
作者：
Mintz, GS;Nissen, SE;Yock, PG
通讯作者：
Yock, PG
影响因子：
9.3
作者：
Tekabe, Yared;Luma, Joane;Johnson, Lynne L.
通讯作者：
Johnson, Lynne L.